Chad McAuliffe
Associate Partner
Expertise:
Chad provides high-impact results for biopharmaceutical companies through strategy and pricing initiatives. His experience includes revenue-optimal pricing for rare disease therapies, market assessments informing product launch decisions and product commercialization, and payer insight research for innovative therapeutics.
Before joining EVERSANA, Chad worked on international engagements across a wide range of therapeutic areas at Simon-Kucher & Partners. His focus there also spanned commercial diagnostic strategy, global resource development, and value-based contract testing. Prior to his role at Simon-Kucher, Chad was a Business Intake Paralegal at Keefe Disability Law, where he grew familiar with Centers for Medicare and Medicaid Services programs and helped to grow the firm’s client base through direct customer outreach.
Chad earned a Bachelor of Arts degree in English literature from Brown University and was in the University Honors Program.
Articles by Chad McAuliffe
Most Favored Nation Pricing | Insights and Implications for Manufacturers
The EVERSANA MANAGEMENT CONSULTING team provides an overview of the recent developments and shares their views on the strategic implications for manufacturers. Manufacturers must act decisively to mitigate Most Favored Nation (MFN) exposure through global pricing strategy, stakeholder engagement, and confidential contracting. Develop evidence dossiers for therapeutic value and negotiation leverage Participate in CMS public comment periods and listening sessions Consider raising prices or delaying launches in OECD reference countries Reassess global launch sequencing to avoid anchoring U.S. prices to low-cost markets Explore value-based or net-price contracting to maintain access Engage the U.S. administration diplomatically to support trade efforts aimed at increasing OUS prices Work proactively with OUS governments to […]
Price Right or Pay Later
Dive into the intricate world of pharmaceutical pricing with “Price Right or Pay Later” by Chad McAuliffe, and Andrew Therrien. In this groundbreaking paper, EVERSANA exposes the critical yet often overlooked nuances of pricing strategies in the pharmaceutical industry. Through meticulous analysis and real-world examples, discover why setting the right price at launch can make or break a product’s commercial success. From navigating payer dynamics to mastering lifecycle management, this paper unveils a comprehensive approach to pricing that promises sustainable revenue in an ever-evolving market. Don’t miss your chance to revolutionize your pricing strategy and secure your brand’s competitive edge. Complete the form below to download the full paper.